Formation of an independent special committee; delay in publication and despatch of 2026 interim report; and continued suspension of trading
Filed with HKEX · Stock code 2592 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Cloudbreak Pharma
- Cloudbreak Pharma Announces Results of First-of-Its-Kind Patient Survey on Pinguecula, Confirming Significant Unmet Need and Impact on Quality of Life
- Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
- Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum
- Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026